Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DTC Pre-review Requirement Broadly Defined Under FDA Draft Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency’s draft guidance on prereview of television advertisements also requires companies to submit the information they rely on to support claims in an ad.

You may also be interested in...

FDA’s Promotional Assessments Reorganized Around Specialty, Not Target Audience

The two divisions within the Office of Prescription Drug Promotion are renamed the divisions of advertising and promotion review I and II; they will each have four teams operating within them in a structure akin to the Office of New Drugs.

DTC Held Hostage? FDA Pre-Review of TV Ads May Delay Rx Campaigns

FDA is proposing changes to its regulation of television advertising for prescription drugs with a mandatory pre-review of ads for certain products. The agency says it has the resources to complete all reviews on time. But stakeholders worry that the draft requirements would delay campaigns and make DTC advertising more expensive. It’s not like there’s a good alternative: jumping the gun on DTC carries its own set of risks.

FDA’s TV Ad Review Is Unconstitutional, PhRMA Says, Or Maybe Should Be A Reg

A draft guidance that outlines six categories of drug ads FDA wants submitted for prior review is a violation of advertisers’ free speech rights, the industry group argues. Other comments float a storyboard compromise.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts